Study Enrollment

Your details will not be published or shared.

Clinical Trial

Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

This study focuses on people with generalized Myasthenia Gravis (gMG) who have used complement component 5 (C5) inhibition therapies (referred to as C5IT) such as Soliris. The purpose of this study is to examine 1) how well C5IT treats gMG over time and 2) the safety of C5IT. We will follow study participants for up to 5 years.

Eligibility Criteria

  • Inclusion Criteria Has gMG and has received treatment with a C5IT at the time of enrollment. Must have all of the following historical data available (within 6 months prior to the initiation of C5IT) MGFA class (worst class to date) MG-ADL Score MGC Exclusion Criteria Currently enrolled in an Alexion-sponsored clinical drug study for treatment of gMG

Contact Information

    Brandy Quarles

    (706) 721-2681